Le Lézard
Classified in: Health
Subject: FDA

Breckenridge Announces Final Approval of its ANDA for Everolimus Tablets (generic for Zortress®)

BERLIN, Conn., June 1, 2021 /PRNewswire/ -- Breckenridge Pharmaceutical, Inc. announces today that the U.S. Food and Drug Administration has granted final approval of its Abbreviated New Drug Application for Everolimus Tablets (generic for Zortress®). This product was developed in collaboration with Natco Pharma Limited. According to industry sales data, Zortress and its therapeutic equivalents generated annual sales of $162 million during the twelve months ending March 2021.  Breckenridge plans to launch Everolimus Tablets in 0.25mg, 0.5mg and 0.75mg strengths during the third quarter of 2021 in a blister card packaging configuration.

About Breckenridge:
Breckenridge Pharmaceutical, Inc., a subsidiary of Towa Pharmaceutical (Osaka, Japan), partners with manufacturers nationwide and around the world to bring quality, cost-effective generic pharmaceuticals to U.S. patients.  With our dedication to customer service, on-time delivery, reliable supply and quality manufacturing, we improve the health and quality of life of the patients we and our customers serve.

About Natco:
Natco Pharma Limited is a global generic pharmaceutical research, development, manufacturing and marketing company. The company was established in 1981 in India. Natco supplies pharmaceutical products to over 50 countries across the globe, including the United States. Natco focuses on the development and manufacturing of oncology and other specialty pharmaceuticals.

For further information, please contact:
Breckenridge Pharmaceutical, Inc.
Robert Gasparino, Associate Vice President ? Business Development
Tel: 860-828-8140
E-mail: rgasparino@bpirx.com

*All brand names and trademarks are the property of their respective owners.

SOURCE Breckenridge Pharmaceutical, Inc.

These press releases may also interest you

at 06:50
Merck , known as MSD outside the United States and Canada, today announced positive top-line results from two pivotal Phase 3 trials of the investigational, once-daily oral fixed dose combination pill of doravirine/islatravir (DOR/ISL) in adults with...

at 06:47
Announcement by leading chemicals company in line with its 'Chemistry for Better Living' commitment, providing clear pathway to improving people's quality of life through transformation to low carbon business Ambitious plan will use Three-Pillar Low...

at 06:45
Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc. ("Bausch Health"), and Clearside Biomedical, Inc. ("Clearside"), a biopharmaceutical company revolutionizing the...

at 06:45
Mallinckrodt plc, a global biopharmaceutical company, today announced results from a retrospective medical chart review study examining treatment patterns and outcomes in hospitalized patients with esophageal variceal hemorrhage (EVH) and liver...

at 06:40
Today, on the occasion of the World Health Summit 2021, Boehringer Ingelheim shares an update on its strategic approach to sustainable development. A commitment to initiatives that contribute to ?MORE HEALTH', one of the three pillars within the...

at 06:40
DarioHealth Corp. ("Dario," "DarioHealth" or the "Company") , a leader in the global digital therapeutics (DTx) market, announced today that it has entered into a contract with a U.S. national employer (the "Employer") for the Company's full...

News published on 1 june 2021 at 11:34 and distributed by: